STOCK TITAN
  1. Home
  2. News
  3. MRK

Merck & Co Inc - MRK STOCK NEWS

Welcome to our dedicated news page for Merck & Co (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & Co.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Merck & Co's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Merck & Co's position in the market.

News
Merck Ranks No. 1 on Newsweek’s List of America’s Most Responsible Companies 2024
Rhea-AI Summary
Merck (NYSE:MRK) has been recognized as America's Most Responsible Company by Newsweek, securing the top spot for the first time and achieving a perfect score of 100/100 in corporate governance. This marks the second consecutive year that Merck has been acknowledged as an industry leader, highlighting its commitment to responsible business practices. The company's chairman and CEO, Robert M. Davis, expressed pride in this recognition, emphasizing Merck's dedication to enabling a safe and healthy future for people and communities globally. Merck's achievements on multiple esteemed lists, including CNBC and JUST Capital's Most JUST Companies and Barron's 100 Most Sustainable U.S. Companies, further solidify its reputation as a leader in corporate responsibility and sustainability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.15%
Tags
none
-
News
Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer
Rhea-AI Summary
Merck (MRK) and Moderna (MRNA) have initiated the second clinical trial in the INTerpath program, a Phase 3 randomized clinical trial evaluating V940 (mRNA-4157) in combination with KEYTRUDA as adjuvant treatment in patients with completely resected non-small cell lung cancer. This represents a rapid expansion in research for individualized neoantigen therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.6%
Tags
clinical trial
-
News
Merck Animal Health Receives Positive CVMP Opinion for an Injectable Formulation of BRAVECTO® (Fluralaner) for Use in Dogs
Rhea-AI Summary
Merck Animal Health (NYSE:MRK) announced that the European Medicines Agency's Committee for Veterinary Medicinal Products issued a positive opinion for BRAVECTO, an injectable formulation for the treatment and persistent killing of fleas and ticks in dogs. If approved by the European Commission, this once-yearly medication will provide long-lasting protection for pets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.6%
Tags
none
News
Merck and Eisai Provide Update on Phase 3 LEAP-001 Trial Evaluating (pembrolizumab) Plus LENVIMA® (lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma
Rhea-AI Summary
Merck (MRK) and Eisai Announce Disappointing Results for KEYTRUDA Plus LENVIMA in Phase 3 LEAP-001 Trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.13%
Tags
clinical trial
-
News
Merck Announces KEYLYNK-008 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LYNPARZA® (olaparib) for Patients With Metastatic Squamous Non-Small Cell Lung Cancer to Stop for Futility
Rhea-AI Summary
Merck (MRK) stops Phase 3 KEYLYNK-008 trial for KEYTRUDA and LYNPARZA combination in metastatic squamous NSCLC due to lack of improvement in overall survival. KEYTRUDA-based combinations in NSCLC are being evaluated in other studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.66%
Tags
none
-
News
Merck Announces Findings from Phase 2 KeyVibe-002 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab in Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)
Rhea-AI Summary
Merck (MRK) presented full results from the non-registrational Phase 2 KeyVibe-002 trial at ESMO I-O 2023 Annual Meeting. The trial evaluated vibostolimab/pembrolizumab, an investigational coformulation, for metastatic non-small cell lung cancer patients. The coformulation, with or without docetaxel, extended median progression-free survival by 2.4 months compared to docetaxel alone. However, the results did not reach statistical significance. Vibostolimab/pembrolizumab alone did not show an improvement in median PFS compared to docetaxel alone. Key secondary endpoints, including overall survival, overall response rate, and duration of response, were also presented. The safety profile was consistent with no new safety signals observed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.66%
Tags
clinical trial
News
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer
Rhea-AI Summary
Merck (MRK) has announced that the FDA has accepted a new supplemental Biologics License Application (sBLA) for KEYTRUDA, in combination with Padcev, for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma. The sBLA is based on data from the Phase 3 KEYNOTE-A39 trial, showing a significant improvement in overall survival and progression-free survival versus chemotherapy. The FDA has set a target action date of May 9, 2024, for review.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.96%
Tags
none
-
News
AWS and Accenture Help Merck Use Cloud Technology to Reduce Drug Discovery Time and Accelerate Clinical Trial Development
Rhea-AI Summary
Amazon Web Services (AWS) is working with Accenture to help Merck (MRK) move its IT infrastructure to AWS, accelerate scientific research and discovery, and transform its value chain. Merck is using AWS analytics and AI services across its divisions, including a manufacturing platform to improve product availability and yield. The cloud migration will enable Merck to redirect resources to other strategic programs, with significant IT operational savings already realized.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.23%
Tags
clinical trial
-
News
Merck Announces First-Quarter 2024 Dividend
Rhea-AI Summary
Merck (MRK) declares a quarterly dividend of $0.77 per share for Q1 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.23%
Tags
dividends
News
Merck’s V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults, Demonstrated Superior Immunogenicity for 10 of 11 Unique Serotypes Compared to PCV20 in Adults 50 Years of Age and Older
Rhea-AI Summary
Merck (MRK) announced the results of the Phase 3 trial, STRIDE-3, evaluating V116, the company’s 21-valent pneumococcal conjugate vaccine designed to protect adults. The trial showed that V116 elicited non-inferior immune responses compared to PCV20 for 10 serotypes common to both vaccines in adults 50 years and older. V116 also had a safety profile comparable to PCV20. The results are being presented at the World Vaccine Congress West Coast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.23%
Tags
none
Stock MRK logo
Merck & Co Inc

NYSE:MRK

MRK Rankings

#26 Ranked by Market Cap
#1895 Ranked by Stock Gains
#1155 Ranked by Dividends

MRK Stock Data

318.50B
2.53B
0.05%
78.56%
0.77%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Kenilworth

About MRK

Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of whom it was once the American arm. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada.